Literature DB >> 1891364

An intron binding protein is required for transformation ability of p53.

S W Beenken1, G Karsenty, L Raycroft, G Lozano.   

Abstract

Regulatory elements in intron sequences have been identified for several eukaryotic genes. The fourth intron of p53 is known to increase expression of p53 in a position dependent manner. We asked whether p53 intron 4 sequences interacted with DNA binding proteins to exact their effect. Three overlapping DNA fragments spanning the 5' end of p53 intron 4 were determined to specifically interact with protein in nuclear extracts from several cell lines by band shift analysis. Methylation interference experiments were used to identify purine residues involved in this protein-DNA interaction. Two G nucleotides were identified at intron 4 positions 33 and 44 and these were replaced by T and C, respectively. These two single base pair substitutions in the intron resulted in 1) lack of protein binding and 2) decreased expression of p53 as measured by a transformation assay. Thus the binding of protein to p53 intron 4 was shown to have functional significance. These experiments demonstrated a specific protein binding region in the 5' end of intron 4 critical for p53 expression and distinct from those elements already known to be involved in splicing.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1891364      PMCID: PMC328718          DOI: 10.1093/nar/19.17.4747

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  38 in total

1.  The p53 proto-oncogene can act as a suppressor of transformation.

Authors:  C A Finlay; P W Hinds; A J Levine
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

2.  Identification of an altered splice site in Ashkenazi Tay-Sachs disease.

Authors:  E Arpaia; A Dumbrille-Ross; T Maler; K Neote; M Tropak; C Troxel; J L Stirling; J S Pitts; B Bapat; A M Lamhonwah
Journal:  Nature       Date:  1988-05-05       Impact factor: 49.962

3.  Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; S H Advani; S Benchimol; M J Cline
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Participation of p53 cellular tumour antigen in transformation of normal embryonic cells.

Authors:  D Eliyahu; A Raz; P Gruss; D Givol; M Oren
Journal:  Nature       Date:  1984 Dec 13-19       Impact factor: 49.962

5.  Equilibria and kinetics of lac repressor-operator interactions by polyacrylamide gel electrophoresis.

Authors:  M Fried; D M Crothers
Journal:  Nucleic Acids Res       Date:  1981-12-11       Impact factor: 16.971

6.  Contacts between Escherichia coli RNA polymerase and an early promoter of phage T7.

Authors:  U Siebenlist; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

7.  Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences.

Authors:  G Lozano; A J Levine
Journal:  Mol Carcinog       Date:  1991       Impact factor: 4.784

8.  Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53.

Authors:  J R Jenkins; K Rudge; G A Currie
Journal:  Nature       Date:  1984 Dec 13-19       Impact factor: 49.962

9.  A gel electrophoresis method for quantifying the binding of proteins to specific DNA regions: application to components of the Escherichia coli lactose operon regulatory system.

Authors:  M M Garner; A Revzin
Journal:  Nucleic Acids Res       Date:  1981-07-10       Impact factor: 16.971

10.  Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.

Authors:  L F Parada; H Land; R A Weinberg; D Wolf; V Rotter
Journal:  Nature       Date:  1984 Dec 13-19       Impact factor: 49.962

View more
  7 in total

1.  Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer.

Authors:  Joellen M Schildkraut; Ellen L Goode; Merlise A Clyde; Edwin S Iversen; Patricia G Moorman; Andrew Berchuck; Jeffrey R Marks; Jolanta Lissowska; Louise Brinton; Beata Peplonska; Julie M Cunningham; Robert A Vierkant; David N Rider; Georgia Chenevix-Trench; Penelope M Webb; Jonathan Beesley; Xiaoqing Chen; Catherine Phelan; Rebecca Sutphen; Thomas A Sellers; Leigh Pearce; Anna H Wu; David Van Den Berg; David Conti; Christopher K Elund; Rebecca Anderson; Marc T Goodman; Galina Lurie; Michael E Carney; Pamela J Thompson; Simon A Gayther; Susan J Ramus; Ian Jacobs; Susanne Krüger Kjaer; Estrid Hogdall; Jan Blaakaer; Claus Hogdall; Douglas F Easton; Honglin Song; Paul D P Pharoah; Alice S Whittemore; Valerie McGuire; Lydia Quaye; Hoda Anton-Culver; Argyrios Ziogas; Kathryn L Terry; Daniel W Cramer; Susan E Hankinson; Shelley S Tworoger; Brian Calingaert; Stephen Chanock; Mark Sherman; Montserrat Garcia-Closas
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

2.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1991-11-25       Impact factor: 16.971

Review 3.  Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside.

Authors:  Ming-Feng Lin; Chung-Yu Lan
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

4.  Association of specific genotype and haplotype of p53 gene with cervical cancer in India.

Authors:  S Mitra; C Misra; R K Singh; C K Panda; S Roychoudhury
Journal:  J Clin Pathol       Date:  2005-01       Impact factor: 3.411

5.  p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis.

Authors:  S M Post; A Quintás-Cardama; T Terzian; C Smith; C M Eischen; G Lozano
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

6.  Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines.

Authors:  I B Runnebaum; X W Tong; V Moebus; V Heilmann; D G Kieback; R Kreienberg
Journal:  Hum Genet       Date:  1994-06       Impact factor: 4.132

7.  Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.

Authors:  S Wang-Gohrke; W Weikel; H Risch; D Vesprini; J Abrahamson; C Lerman; A Godwin; R Moslehi; O Olipade; J S Brunet; E Stickeler; D G Kieback; R Kreienberg; B Weber; S A Narod; I B Runnebaum
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.